All In Biotech

Drug Trial Radar · NCT06159101

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

A Randomized, Intravenous Single-Dose, Parallel, Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX13 and YERVOY® (US-, EU-, and CN-Sourced) in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

304

Planned (sponsor's estimate)

Start

Nov 28, 2023

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Dec 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects

Conditions

  • Healthy Male Volunteers

Interventions

  • HLX13Drug

    A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.

  • CN-sourced ipilimumabDrug

    A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.

  • EU-sourced ipilimumab groupDrug

    A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.

  • US-sourced ipilimumab groupDrug

    A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf)Time frame: Up to Day 90
  2. Maximum (peak) serum drug concentration (Cmax)Time frame: Up to Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Anhui, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.